Last reviewed · How we verify
Measles Vaccine at 18 months of age — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Measles Vaccine at 18 months of age (Measles Vaccine at 18 months of age) — Medical Research Council Unit, The Gambia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Measles Vaccine at 18 months of age TARGET | Measles Vaccine at 18 months of age | Medical Research Council Unit, The Gambia | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Measles Vaccine at 18 months of age CI watch — RSS
- Measles Vaccine at 18 months of age CI watch — Atom
- Measles Vaccine at 18 months of age CI watch — JSON
- Measles Vaccine at 18 months of age alone — RSS
Cite this brief
Drug Landscape (2026). Measles Vaccine at 18 months of age — Competitive Intelligence Brief. https://druglandscape.com/ci/measles-vaccine-at-18-months-of-age. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab